---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-003293"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2023-02-21T23:59:59+00:00"
generated_at: "2026-06-19T06:53:34.516191+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Clearside Biomedical CMO Thomas Ciulla resigns, becomes advisor under consulting agreement

## Summary
- Thomas Ciulla resigned as CMO and CDO effective Feb 17, 2023; will serve as Chairman of Scientific Advisory Board and Chief Medical Advisor – Retina.
- Consulting fee of $8,000 per month; initial term one year, renewable at Company's option.
- Stock options continue vesting through Aug 31, 2023 (Jan 4, 2023 option through Jan 4, 2024); RSU vesting ceased on Feb 17, 2023.

## SEC filing metadata
- accession: 0000950170-23-003293
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2023-02-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017023003293/0000950170-23-003293-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017023003293/clsd-20230217.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-003293
- JSON: https://secwatch.observer/filing/0000950170-23-003293.json
- Plain text: https://secwatch.observer/filing/0000950170-23-003293.txt

## Key facts
- Executive change
  Thomas Ciulla resigned as Chief Medical Officer and Chief Development Officer at Clearside Biomedical, Inc..
  - Action: resigned
  - Role: Chief Medical Officer and Chief Development Officer
  source text: Thomas Ciulla provided Clearside Biomedical, Inc. (the “ Company ”) notice of his resignation from his position as Chief Medical Officer and Chief Development Officer of the Company, with such resignation to be effective on February 17, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1539029/000095017023003293/0000950170-23-003293-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.